New Strategies for Multiple Myeloma Care: Next Steps for the Future

Join us for this year’s International Myeloma Foundation and Clinical Care Options cosponsored symposium, where an esteemed panel of international experts will offer their perspectives on practice-changing data and optimal management of patients with myeloma.

Interact with the experts as they debate current clinical questions as well as the immediate and future implications for therapeutic decision making based on  emerging clinical data.

Friday Satellite Symposium preceding the 60th ASH Annual Meeting & Exposition.


12:30 PM- 1:00 PM Registration and Lunch

1:00 PM- 1:05 PM Welcome and Introduction
Brian G.M. Durie, MD, Program Director and Moderator

1:05 PM - 3:40 PM Case Discussions

  • Case Discussion 1: Risk Stratification of Plasma Cell Disorders
  • Case Discussion 2: Are we ready for personalized therapy in Newly Diagnosed MM?
  • Case Discussion 3: Considering the Recent Data on Transplantation, Consolidation, and Maintenance After Induction Therapy
  • Case Discussion 4: Advances in the Optimal Choice of Therapeutic Strategies for Patients With Relapsed/Refractory Disease

Faculty Panel Discussion and Audience Questions
For each case presented, faculty will discuss available clinical data that could guide the treatment choice for the case

3:40 PM - 3:50 PM Review of a 2019 Treatment Algorithm for Multiple Myeloma

3:50 PM - 4:00 PM Final Thoughts and Take-home Conclusions
Brian G.M. Durie, MD, Program Director and Moderator


Date / Time
Event Details


Program Director
Brian G.M. Durie, MD

Medical Director, AMyC
Co-Chair Myeloma Committee, SWOG
Chairman, International Myeloma Foundation
Specialist in Multiple Myeloma and Related Disorders
Cedars-Sinai Outpatient Cancer Center
Los Angeles, California

Shaji Kumar, MD

Department of Hematology
Mayo Clinic
Rochester, Minnesota

Philippe Moreau, MD

Professor of Clinical Hematology
Hematology Department
University Hospital Hôtel-Dieu
Nantes, France

S. Vincent Rajkumar, MD

Professor of Medicine
Chair, Myeloma Amyloidosis Dysproteinemia Group
Mayo Clinic
Rochester, Minnesota

Jesús F. San-Miguel, MD, PhD

Director of Clinical and Translational Medicine
Universidad de Navarra
Pamplona, Spain

Goal Statement
The goal of this educational initiative is to improve participants’ competence in and performance at applying practice-changing clinical data and expert recommendations to optimize the care of their patients with myeloma.

Target Audience 
This program is intended for physicians and other healthcare providers who care for patients with multiple myeloma.

Learning Objectives 

  • Initiate treatment for appropriate patients based on available data and current diagnosis and staging criteria for multiple myeloma
  • Plan individualized treatment strategies for patients with multiple myeloma through consideration of the available clinical data along with risk assessment, comorbidities, and patient age/fitness
  • Choose the optimal combination of agents to treat patients with relapsed multiple myeloma, particularly difficult-to-treat patient populations such as the elderly, those with high-risk cytogenetic abnormalities, and those with refractory disease
  • Integrate recently approved, as well as novel, monoclonal antibody–based triplets and quadruplets into existing treatment strategies for patients with multiple myeloma
  • Identify ongoing trials of next generation novel targeted agents, antibodies, and immunotherapies to aid referral of patients with multiple myeloma for study participation


Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower, International Myeloma Foundation and Clinical Care Options, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
The Annenberg Center for Health Sciences at Eisenhower requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to the Annenberg Center for Health Sciences at Eisenhower policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.